by Daniel X. Thomas
EP 3 525 706 B1 relates to the field of Cold Atmospheric Plasma (CAP) treatment of therapy-refractory Actinic Keratosis, wherein the cold atmospheric plasma is an argon-containing plasma.
Brief outline of the procedure
The OD rejected the opposition and Opponent 2 appealed.
The board decided that claim 1 as granted lack IS over D1=US 2013/0345620 in view an expectation of success.
by Daniel X. Thomas
EP 3 550 985 B1 relates to a nutritional composition for improving cells membranes in infants.
Brief outline of the case
The OD revoked the patent, as some requests were lacking N over D5=WO 2012/173485 or did not comply with Art 53(c).
by Daniel X. Thomas
EP 2 962 690 B1 is a 2d generation divisional and relates to (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline1,3-dione, or a pharmaceutically acceptable polymorph, salt, solvate or hydrate thereof, and to the (+) enantiomer for use as a medicament.
Brief outline of the case
The patent was maintained according to AR3.
by Daniel X. Thomas
EP 2 397 156 relates to “Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway”.
Claim 1 is drafted in the form of a purpose-limited product claim, pursuant to Art 54(5), and is directed to a compound that reduces the activity or expression of a Programmed Cell Death-1 (PD-1) polypeptide=”PD-1 inhibitor”,
by Daniel X. Thomas
EP 2 371 361 B1 relates to methods to mobilise progenitor/stem cells in subjects by administering certain polyamines.
Brief outline of the case
The patent was maintained by the OD according to AR6.
The proprietor and opponents 1,